Aquamarine Fund

Aquamarine Therapeutics is a preclinical-stage biotechnology company dedicated to developing transformative therapies for rare genetic kidney diseases, with a primary focus on Alport syndrome. Spun out from the University of Manchester, the company leverages the pioneering research of Professor Rachel Lennon into the glomerular basement membrane and the extracellular matrix. Their therapeutic approach involves identifying and targeting specific pathways to restore the structural integrity of the kidney's filtering units, which are compromised by mutations in Type IV collagen genes. The company aims to address the significant unmet medical need in Alport syndrome, a condition that currently lacks disease-modifying treatments and frequently progresses to end-stage renal failure.